Adult Pancreas Transplant Recipient Registration Worksheet

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information			
Name:	DOE	B:	
SSN:	Birt	th sex:	
HIC:	Trai Tim	nsplant Date and ne:	
State of Permanent Residence: *			
Permanent Zip: *	-		
-			
Provider Information			
Recipient Center:			
Surgeon Name: *			
NPI#:*			
Donor Information			
UNOS Donor ID #:			
Recovering OPO:			
Donor Type:			
Patient Status			
Primary Diagnosis: *			
Specify:			
Date: Last Seen, Retransplanted or Death			
Patient Status: *	OLIVING		
	ODEAD		
	RETRANSPLANTED		
Primary Cause of Death:			
Specify:			
Contributory Cause of Death:			
Specify:			
Contributory Cause of Death:			
Specify:			
Transplant Hospitalization:			
Date of Admission to Tx Center:*			
Date of Discharge from Tx Center:			
Clinical Information : PRETRANS	SPLANT		
Functional Status: *			
Working for income:*	YES NO UNK		
Working for income.	YES NO OUNK		
Source of Payment: Primary: *			
-			
Specify:			
Height: *	ftin.	cm ST=	
Weight: *	lbs	kg ST=	
вмі:	kg/m ²		
Previous Transplants:			
Previous Transplant Organ	Previous Transplant Date	Previous Transplant Graft Fail Date	
			-
Copyright © 2023 United Ne	etwork for Organ Sharing. All rights r	reserved. OP I'N use only. 091423	

retransplant Dialysis: *	YES NO UNI	•	
If Yes, Date of Most Recent Initiation of Chronic Maintenance Dialysis:			ST=
verage Daily Insulin Units:*		units/kg/day	ST=
erum Creatinine at Time of Tx: *		mg/dl	ST=
iral Detection:			- Ш
HIV Serostatus: ★	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Dis	close	
CMV Status∗	Positive		
	Negative		
	ONot Done		
	OUNK/Cannot Dis	close	
HBV Surface Antibody Total ∗	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Dis	close	
HBV Core Antibody: ∗	Positive		
·	Negative		
	Not Done		
	OUNK/Cannot Dis	close	
HBV Surface Antigen: *			
nov Surface Artigen. *	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Dis	ciose	
HCV Serostatus: *	Positive		
	Negative		
	ONot Done		
	OUNK/Cannot Dis	close	
EBV Serostatus: *	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Dis	close	
accination Status:			
Did the recipient receive Hepatitis B vaccines prior to transplant?: $\!$	YES NO UNI	(
Reason not vaccinated:	Immunity		
	Medical precauti	ion	
	Time constraints	5	
	Patient objection	n	
	Product out of s	tock	
	Other, specify		
Specify:			
IAT Results:			

HIV NAT: ∗	Positive		
	Negative		
	ONot Done		
	OUNK/Cannot Disclose		
HBV NAT: ∗	Positive		
	Negative		
	ONot Done		
	OUNK/Cannot Disclose		
HCV NAT: *			
NOV IVAL.	Positive		
	Negative		
	ONOT Done		
	OUNK/Cannot Disclose		
Malignancies between listing and transplant: *	YES NO UNK		
This question is NOT applicable for patients receiving living do	onor transplants who were never on the waiting list.		
If yes, specify type:	□Skin Melanoma		
	Skin Non-Melanoma		
	□CNS Tumor		
	Genitourinary		
	□Breast		
	Thyroid		
	☐Tongue/Throat/Larynx		
	□Lung		
	□Leukemia/Lymphoma		
	Liver		
	Other, specify		
Specify:			
Clinical Information : TRANSPLANT PRO	CEDURE		
Multiple Organ Recipient			
Were extra vessels used in the transplant procedure: $ \\$			
Procedure Type:			
Surgical Information:			
Graft Placement: *	OINTRA-PERITONEAL		
	RETRO-PERITONEAL		
	OPARTIAL INTRA/RETRO-PERITONEAL		
Oncenting Techniques			
Operative Technique: *	OPANCREAS ALONE		
	OPANCREAS AFTER KIDNEY		
	OCLUSTER		
	MULTI-ORGAN NON-CLUSTER		
	OPANCREAS WITH KIDNEY DIFFERENT DONOR		
Duct Management: *	○ENTERIC W/ROUX-EN-Y		
	○ENTERIC W/O ROUX-EN-Y		
	Сузтоятому		
	ODUCT INJECTION IMMEDIATE		
	ODUCT INJECTION DELAYED		
	OTHER SPECIFY		
Specify:			
0 1110 0000 17 11 11 11 11	Organ Sharing. All rights reserved. OPTN use only. 091423		

us Vascular Management: *	SYSTEMIC SYSTEM (ILIAC:CAVA)	

	PORTAL SYSTEM (PORTAL OR TRIBUTARIES)
	NA/Multi-organ cluster
Arterial Reconstruction: *	
Arterial Reconstruction: *	CELIAC WITH PANCREAS
	OY-GRAFT TO SPA & SMA OSPA TO SMA DIRECT
	SPA TO SMA WITH INTERPOSITION
	SPA ALONE
	OTHER SPECIFY
Specify:	
Venous Extension Graft: *	YES NO
Preservation Information:	S.22 S.12
Total Pancreas Preservation Time (include Cold, Warm,	hre CT-
Anastomotic time): *	hrs ST=
Organ Check-in Information:	
Pancreas Check- Date: Time: In Date and Time:	Military time Time Zone: ST=
Clinical Information : POST TRANSPLANT Pancreas Graft Status: *	Functioning Failed
If death is indicated for the recipient, report graft status up until I	
Patient using either oral medication or diet for blood sugar control:*	YES NO UNK
Patient on oral medication to control blood sugar?*	YES NO UNK
Date of medications resumed: *	ST=
Patient using diet to control blood sugar:*	YES NO UNK
Patient on insulin?*	YES NO UNK
Date insulin resumed: *	ST=
Average total insulin dosage per day: *	units/kg/day ST=
Insulin duration of use: *	days ST=
C-peptide value:	ng/mL ST=
HbA1c:	% ST=
Date of Graft Failure:	
Pancreas Primary Cause of Graft Failure:	
Specify:	
Contributory causes of graft failure:	
Pancreas Graft/Vascular Thrombosis:	YES NO UNK
Pancreas Infection:	YES NO UNK
Bleeding:	YES NO UNK
Anastomotic Leak:	YES NO UNK
Hyperacute Rejection:	YES NO UNK
Pancreas Acute Rejection:	YES NO UNK
Biopsy Proven Isletitis:	YES NO UNK
Pancreatitis:	YES NO UNK
Other, Specify:	
Pancreas Transplant Complications:	
(Not leading to graft failure.)	
Pancreatitis: *	YES NO UNK
Copyright © 2023 United Network for Or	rgan Sharing. All rights reserved. OPTN use only. 091423

Anastomotic Leak: *	YES NO UNK				
Abscess or Local Infection: *	YES NO UNK				
Pancreas Transplant Complications: Other					
Did patient have any acute rejection episodes between transplant and discharge: $\!\!\!\!\!*$	Yes, at least one episode tre	ated with anti-rej	ection agent		
	Yes, none treated with addit	tional anti-rejectio	n agent		
	○No				
Immunosuppressive Information					
Are any medications given currently for maintenance or anti-rejection: $\!$	○YES ○NO				
Immunosuppressive Medications					
View Immunosuppressive Medications Definitions Of Immunosuppressive Medications					
For each of the immunosuppressive medications listed, select Ind prescribed for the recipient during the initial transplant hospitalizati Induction (Ind) immunosuppression includes all medications give Though the drugs may be continued after discharge for the first 30 Induction agents are usually polyclonal, monoclonal, or IL-2 recept drugs might be used for another finite period for rejection therapy medication indicated, write the total number of days the drug was apart then the total number of days would be 2, even if the second Maintenance (Maint) includes all immunosuppressive medication	ion period, and for what reason. If a len for a short finite period in the period of days after transplant, it will not be use a methylpredni and would be recorded as anti-rejecti actually administered in the space prid dose was given after the patient wa	medication was not of operative period for to issed long-term for im isolone, Campath, Th ion therapy if used fo ovided. For example, s discharged.	the purpose of imunosuppress ymoglobulin, cor this reason. if Simulect wa	e associated box(es preventing acute resive maintenance. or Simulect). Some For each induction as given in 2 doses	s) blank. ejection. of these a week
prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azath rejection episodes, or for induction.					
Anti-rejection (AR) immunosuppression includes all immunosupp post-transplant period or during a specific follow-up period, usually Thymoglobulin). When switching maintenance drugs (example: fron the drugs should not be listed under AR immunosuppression, but s	up to 30 days after the diagnosis of m tacrolimus to cyclosporine; or from	acute rejection (exar mycophenolate mof	nple: methylpr	ednisolone, or	
If an immunosuppressive medication other than those listed is bein Immunosuppressive Medication field, and enter the full name of the	ng administered (e.g., new monoclona	al antibodies), select			<u>.</u>
Drug used for induction, acute rejection, or	maintenance Ind.	Days	ST	Maint	AR
Steroids (prednisone, methylprednisolone, Solumedrol, Medrol)					
Drugs used for induction or acute rejection					
Atgam	Ind.	Days	ST	Maint	AR
Campath (alemtuzumab)					
Cytoxan (cyclophosphamide)					
Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex)					
Rituxan (rituximab)					
. ,					- 11
Simulect (basiliximab)					
Thymoglobulin					
Thymoglobulin					
Thymoglobulin Drugs primarily used for maintenance					
Drugs primarily used for maintenance	Ind.	Days	ST		AR
		Days	ST		AR
Drugs primarily used for maintenance Cyclosporine, select from the following:	Ind.	Days	ST	Maint	AR
Drugs primarily used for maintenance Cyclosporine, select from the following: - Gengraf	Ind.	Days	ST	Maint	AR
Drugs primarily used for maintenance Cyclosporine, select from the following: - Gengraf - Neoral	Ind.	Days	ST	Maint	AR
Drugs primarily used for maintenance Cyclosporine, select from the following: - Gengraf - Neoral - Sandimmune - Generic cyclosporine	Ind.	Days	ST	Maint	AR
Drugs primarily used for maintenance Cyclosporine, select from the following: - Gengraf - Neoral - Sandimmune	Ind.	Days	ST	Maint	AR

Copyright © 2023 United Network for Organ Sharing. All rights reserved. OPTN use only. 091423

- CellCept (MMF)					
- Generic MMF (generic CellCept)					
- Myfortic (mycophenolic acid)					
- Generic Myfortic (generic mycophenolic acid)					
mTOR inhibitors, select from the following:					
- Rapamune (sirolimus)					
- Generic sirolimus					
- Zortress (everolimus)					
Nulojix (belatacept)					
Tacrolimus, select from the following:					
- Astagraf XL (extended release tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Prograf (tacrolimus)					
- Generic tacrolimus (generic Prograf)					
Other drugs	*d	Davis	CT	M-:	
Other immunosuppressive medication, specify:	Ind.	Days	ST	Maint	AR
Other immunosuppressive medication, specify:					

Copyright © 2023 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms